Cargando…

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

BACKGROUND: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Lopez, Jose P, Gonzalez, Ana Maria, Lanza, Paola, Lopez-Jaramillo, Patricio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504901/
https://www.ncbi.nlm.nih.gov/pubmed/37719697
http://dx.doi.org/10.2147/VHRM.S421024
_version_ 1785106825146793984
author Lopez-Lopez, Jose P
Gonzalez, Ana Maria
Lanza, Paola
Lopez-Jaramillo, Patricio
author_facet Lopez-Lopez, Jose P
Gonzalez, Ana Maria
Lanza, Paola
Lopez-Jaramillo, Patricio
author_sort Lopez-Lopez, Jose P
collection PubMed
description BACKGROUND: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. METHODS: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. RESULTS: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percentages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. CONCLUSION: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
format Online
Article
Text
id pubmed-10504901
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105049012023-09-17 Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review Lopez-Lopez, Jose P Gonzalez, Ana Maria Lanza, Paola Lopez-Jaramillo, Patricio Vasc Health Risk Manag Review BACKGROUND: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. METHODS: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. RESULTS: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percentages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. CONCLUSION: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice. Dove 2023-09-12 /pmc/articles/PMC10504901/ /pubmed/37719697 http://dx.doi.org/10.2147/VHRM.S421024 Text en © 2023 Lopez-Lopez et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Lopez-Lopez, Jose P
Gonzalez, Ana Maria
Lanza, Paola
Lopez-Jaramillo, Patricio
Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
title Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
title_full Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
title_fullStr Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
title_full_unstemmed Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
title_short Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
title_sort benefits of the polypill on medication adherence in the primary and secondary prevention of cardiovascular disease: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504901/
https://www.ncbi.nlm.nih.gov/pubmed/37719697
http://dx.doi.org/10.2147/VHRM.S421024
work_keys_str_mv AT lopezlopezjosep benefitsofthepolypillonmedicationadherenceintheprimaryandsecondarypreventionofcardiovasculardiseaseasystematicreview
AT gonzalezanamaria benefitsofthepolypillonmedicationadherenceintheprimaryandsecondarypreventionofcardiovasculardiseaseasystematicreview
AT lanzapaola benefitsofthepolypillonmedicationadherenceintheprimaryandsecondarypreventionofcardiovasculardiseaseasystematicreview
AT lopezjaramillopatricio benefitsofthepolypillonmedicationadherenceintheprimaryandsecondarypreventionofcardiovasculardiseaseasystematicreview